Praxis drops as it posts Q1 results and updates NDA/clinical milestones
Praxis Precision Medicines released a May 7, 2026 corporate update with Q1 2026 results and new clinical/regulatory highlights. The update reiterated FDA acceptance of two NDAs (ulixacaltamide and relutrigine), cited new elsunersen EMBRAVE Part A seizure-reduction data, and guided to multiple near-term trial readouts.
1. What happened today (May 7, 2026)
Praxis Precision Medicines published a corporate update alongside first-quarter 2026 financial results on May 7, 2026, and scheduled an 8:30 a.m. ET conference call the same morning. The release highlighted updated clinical and regulatory milestones while reporting quarterly operating metrics.
2. Key catalyst details
The company reiterated FDA acceptance of NDAs for ulixacaltamide in essential tremor (PDUFA target action date January 29, 2027) and relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies under priority review (PDUFA target action date September 27, 2026). It also referenced elsunersen EMBRAVE Part A results showing a 77% placebo-adjusted reduction in monthly seizures, and pointed to upcoming topline timelines including POWER1 (vormatrigine) expected in Q2 2026 and EMERALD (relutrigine in broad DEEs) expected in Q4 2026.
3. Why shares could be down despite headline progress
Even with constructive pipeline updates, an earnings-day release can pressure the stock if investors focus on quarterly loss, expense growth (R&D and G&A), or lack of new step-change information beyond already-known regulatory events. The market may also be positioning ahead of the next higher-volatility clinical readouts (POWER1 in Q2 2026 and EMERALD in Q4 2026).